Bausch Health [BHC] vs Regencell Bioscience [RGC] Detailed Stock Comparison
Bausch Health
NYSE
Loading...
Regencell Bioscience
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Bausch Health wins in 8 metrics, Regencell Bioscience wins in 3 metrics, with 0 ties. Bausch Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bausch Health | Regencell Bioscience | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 28.85 | N/A | N/A |
| Price-to-Book Ratio | N/A | 878.57 | N/A |
| Debt-to-Equity Ratio | 14,787.76 | 0.01 | Regencell Bioscience |
| PEG Ratio | 1.70 | N/A | N/A |
| EV/EBITDA | 7.62 | -1,523.21 | Regencell Bioscience |
| Profit Margin (TTM) | 0.99% | 0.00% | Bausch Health |
| Operating Margin (TTM) | 18.02% | 0.00% | Bausch Health |
| EBITDA Margin (TTM) | 18.02% | N/A | N/A |
| Return on Equity | 14.29% | -47.77% | Bausch Health |
| Return on Assets (TTM) | 4.35% | -30.65% | Bausch Health |
| Free Cash Flow (TTM) | $1.26B | $-4.01M | Bausch Health |
| 1-Year Return | 27.60% | 5,718.18% | Regencell Bioscience |
| Price-to-Sales Ratio (TTM) | 0.28 | N/A | N/A |
| Enterprise Value | $23.70B | $6.08B | Bausch Health |
| EV/Revenue Ratio | 2.40 | N/A | N/A |
| Gross Profit Margin (TTM) | 69.80% | N/A | N/A |
| Revenue per Share (TTM) | $27 | N/A | N/A |
| Earnings per Share (Diluted) | $0.26 | $-0.01 | Bausch Health |
| Beta (Stock Volatility) | 0.41 | 2.19 | Bausch Health |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bausch Health vs Regencell Bioscience Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bausch Health | -0.13% | -10.19% | 15.05% | 66.44% | 4.46% | -5.67% |
| Regencell Bioscience | 1.91% | -2.44% | -6.36% | 10.15% | 10,566.67% | 9,746.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bausch Health | 27.60% | 44.59% | -55.71% | -96.83% | -67.70% | -57.73% |
| Regencell Bioscience | 5,718.18% | 1,562.34% | 4,471.43% | 4,471.43% | 4,471.43% | 4,471.43% |
Performance & Financial Health Analysis: Bausch Health vs Regencell Bioscience
| Metric | BHC | RGC |
|---|---|---|
| Market Information | ||
| Market Cap | $2.78B | $6.08B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 7,324,500 | 222,439 |
| 90 Day Avg. Volume | 3,405,347 | 558,706 |
| Last Close | $7.49 | $12.80 |
| 52 Week Range | $4.25 - $9.85 | $0.09 - $83.60 |
| % from 52W High | -23.96% | -84.69% |
| All-Time High | $263.81 (Aug 03, 2015) | $950.00 (May 30, 2025) |
| % from All-Time High | -97.16% | -98.65% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | N/A |
| Quarterly Earnings Growth | 13.80% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.00% |
| Operating Margin (TTM) | 0.18% | 0.00% |
| Return on Equity (TTM) | 0.14% | -0.48% |
| Debt to Equity (MRQ) | 14,787.76 | 0.01 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.07 | $0.01 |
| Cash per Share (MRQ) | $4.67 | N/A |
| Operating Cash Flow (TTM) | $1.51B | $-3,881,392 |
| Levered Free Cash Flow (TTM) | $1.35B | $-4,301,837 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Bausch Health vs Regencell Bioscience
| Metric | BHC | RGC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 28.85 | N/A |
| Forward P/E | 1.70 | N/A |
| PEG Ratio | 1.70 | N/A |
| Price to Sales (TTM) | 0.28 | N/A |
| Price to Book (MRQ) | N/A | 878.57 |
| Market Capitalization | ||
| Market Capitalization | $2.78B | $6.08B |
| Enterprise Value | $23.70B | $6.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.40 | N/A |
| Enterprise to EBITDA | 7.62 | -1,523.21 |
| Risk & Other Metrics | ||
| Beta | 0.41 | 2.19 |
| Book Value per Share (MRQ) | $-2.07 | $0.01 |
Financial Statements Comparison: Bausch Health vs Regencell Bioscience
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BHC | RGC |
|---|---|---|
| Revenue/Sales | $2.53B | N/A |
| Cost of Goods Sold | $764.00M | N/A |
| Gross Profit | $1.77B | N/A |
| Research & Development | $159.00M | N/A |
| Operating Income (EBIT) | $457.00M | N/A |
| EBITDA | $776.00M | N/A |
| Pre-Tax Income | $140.00M | N/A |
| Income Tax | $12.00M | N/A |
| Net Income (Profit) | $128.00M | N/A |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BHC | RGC |
|---|---|---|
| Cash & Equivalents | $1.13B | $2.96M |
| Total Current Assets | $5.73B | $8.11M |
| Total Current Liabilities | $4.26B | $193,578 |
| Long-Term Debt | $21.23B | $25,934 |
| Total Shareholders Equity | $-240.00M | $8.22M |
| Retained Earnings | $-9.88B | $-21.62M |
| Property, Plant & Equipment | N/A | $84,780 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BHC | RGC |
|---|---|---|
| Operating Cash Flow | $236.00M | N/A |
| Capital Expenditures | $-115.00M | N/A |
| Free Cash Flow | $87.00M | N/A |
| Debt Repayment | $-168.00M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BHC | RGC |
|---|---|---|
| Shares Short | 7.29M | 2.25M |
| Short Ratio | 4.58 | 1.15 |
| Short % of Float | 0.02% | 0.02% |
| Average Daily Volume (10 Day) | 7,324,500 | 222,439 |
| Average Daily Volume (90 Day) | 3,405,347 | 558,706 |
| Shares Outstanding | 367.84M | 13.01M |
| Float Shares | 187.72M | 18.43M |
| % Held by Insiders | 0.11% | 0.96% |
| % Held by Institutions | 0.69% | 0.00% |
Dividend Analysis & Yield Comparison: Bausch Health vs Regencell Bioscience
| Metric | BHC | RGC |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | $0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |